Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-18 · Built: 2026-10-18 · 中文

← United States · Coverage record

US · SEC FORM 4

Braveheart Bio, Inc.

BRVE · Nasdaq · CIK 0002131524 · Healthcare · Biotechnology

INSIDER SIGNAL

85.8 / 100

10 buyers · 13 purchase transaction lines · $159.0M gross purchase

WHY THIS SIGNAL?

Buyer breadthStrong
Purchase sizeStrong
RoleModerate
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+35.0 / 35
Purchase size+24.8 / 25
Role+13.0 / 20
Recency+3.0 / 10
Conviction+10.0 / 10

What is holding the score back?

  • ⚠ Role scores low · most senior buyer: CEO and President (CEO, chair and 10% owners score lowest)
  • ⚠ Purchase activity is becoming less recent
  • ✓ Cluster breadth is broad · 4+ insiders

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
AH Bio Fund IV, L.P.; AH Equity Partners Bio IV, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN ATenPercentOwner
○●
Chimovits ErezDirector,TenPercentOwner
○●
ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLCDirector,TenPercentOwner
○●
Forbion Growth III Management B.V.; Forbion Growth Opportunities Fund III Cooperatief U.A.; Forbion Ventures Fund VII Cooperatief U.A.; Forbion Ventures VII Management B.V.TenPercentOwner
○●
Jiangsu Hengrui Pharmaceuticals Co., Ltd.TenPercentOwner
○
Rickey James PaulChief Financial Officer
●
● Purchase▼ Sale○ Other

Showing the six most active owners; 5 additional owner(s) remain in Form 4 evidence.

Purchase breadth & concentration

QUALIFYING BUYERS10
PURCHASE CONCENTRATION41%Largest buyer: Forbion Growth III Management B.V.; Forbion Growth Opportunities Fund III Cooperatief U.A.; Forbion Ventures Fund VII Cooperatief U.A.; Forbion Ventures VII Management B.V. · $64.8M
CLUSTER BUYING · 15D10 insidersPeak activity: 2026-08-07–2026-08-07

Roles in the peak window: CEO and President, Chief Development Officer, Chief Financial Officer, Director, Director,TenPercentOwner, TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

SIGNAL HISTORY

85.8 / 100

Latest recorded score

↓ -0.1 ptsversus the previous recorded snapshot
  1. 86.0
  2. 86.0
  3. 85.9
  4. 85.9
  5. 85.8

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

13Purchases
0Sales
6Other Form 4 lines
11SEC filings · 365 days
BUYING13 qualifying P line(s) · 180 days
SELLING0 sale line(s) · context only
OTHER6 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot assessed

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-26.5%
3M
—
6M
—
12M
—

Volatility & liquidity

Volatility
88.5%
Beta
—
Avg daily value
USD 11.0M

Valuation

Market cap
USD 1.8B
P/E
—

Fundamentals

Profit margin
—
ROE
—
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-09-03 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
4,128,974
Previous report
2,461,086
Avg daily volume
809,950
Days to cover
5.1

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-07ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLCPurchase (P)Common Stock1,940,000USD 18.00USD 34,920,000SEC filing ↗
2026-08-07Chimovits ErezPurchase (P)Common Stock1,940,000USD 18.00USD 34,920,000SEC filing ↗
2026-08-07AH Bio Fund IV, L.P.; AH Equity Partners Bio IV, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN APurchase (P)Common Stock1,100,000USD 18.00USD 19,800,000SEC filing ↗
2026-08-07Viehbacher ChristopherPurchase (P)Common Stock83,333USD 18.00USD 1,499,994SEC filing ↗
2026-08-07Rickey James PaulPurchase (P)Common Stock27,777USD 18.00USD 499,986SEC filing ↗
2026-08-07Murdoch TravisPurchase (P)Common Stock83,333USD 18.00USD 1,499,994SEC filing ↗
2026-08-07Malek David IPurchase (P)Common Stock4,166USD 18.00USD 74,988SEC filing ↗
2026-08-07Lubner David CharlesPurchase (P)Common Stock55,555USD 18.00USD 999,990SEC filing ↗
2026-08-07Forbion Growth III Management B.V.; Forbion Growth Opportunities Fund III Cooperatief U.A.; Forbion Ventures Fund VII Cooperatief U.A.; Forbion Ventures VII Management B.V.Purchase (P)Common Stock3,600,000USD 18.00USD 64,800,000SEC filing ↗
2026-08-07Anderson Michele A.Purchase (P)Common Stock1,111USD 18.00USD 19,998SEC filing ↗

Form 4 evidence

19 transaction lines in the latest 365-day window; 19 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-07ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLCPurchase (P)Common Stock1,940,000USD 18.00USD 34,920,000SEC filing ↗
2026-08-07ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLCC (C)Common Stock9,132,420USD —USD —SEC filing ↗
2026-08-07Chimovits ErezPurchase (P)Common Stock1,940,000USD 18.00USD 34,920,000SEC filing ↗
Show recent Form 4 evidence (15 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-08-07ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLCPurchase (P)Common Stock1,940,000USD 18.00USD 34,920,000SEC filing ↗
2026-08-07ORBIMED ADVISORS LLC; OrbiMed Capital GP IX LLC; OrbiMed Genesis GP LLCC (C)Common Stock9,132,420USD —USD —SEC filing ↗
2026-08-07Chimovits ErezPurchase (P)Common Stock1,940,000USD 18.00USD 34,920,000SEC filing ↗
2026-08-07Chimovits ErezC (C)Common Stock9,132,420USD —USD —SEC filing ↗
2026-08-07AH Bio Fund IV, L.P.; AH Equity Partners Bio IV, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN APurchase (P)Common Stock1,100,000USD 18.00USD 19,800,000SEC filing ↗
2026-08-07AH Bio Fund IV, L.P.; AH Equity Partners Bio IV, L.L.C.; Andreessen Marc L; HOROWITZ BENJAMIN AC (C)Common Stock9,132,420USD —USD —SEC filing ↗
2026-08-07Jiangsu Hengrui Pharmaceuticals Co., Ltd.C (C)Common Stock7,420,091USD —USD —SEC filing ↗
2026-08-07Viehbacher ChristopherPurchase (P)Common Stock83,333USD 18.00USD 1,499,994SEC filing ↗
2026-08-07Rickey James PaulPurchase (P)Common Stock27,777USD 18.00USD 499,986SEC filing ↗
2026-08-07Murdoch TravisPurchase (P)Common Stock83,333USD 18.00USD 1,499,994SEC filing ↗
2026-08-07Malek David IPurchase (P)Common Stock4,166USD 18.00USD 74,988SEC filing ↗
2026-08-07Lubner David CharlesPurchase (P)Common Stock55,555USD 18.00USD 999,990SEC filing ↗
2026-08-07Forbion Growth III Management B.V.; Forbion Growth Opportunities Fund III Cooperatief U.A.; Forbion Ventures Fund VII Cooperatief U.A.; Forbion Ventures VII Management B.V.Purchase (P)Common Stock3,600,000USD 18.00USD 64,800,000SEC filing ↗
2026-08-07Forbion Growth III Management B.V.; Forbion Growth Opportunities Fund III Cooperatief U.A.; Forbion Ventures Fund VII Cooperatief U.A.; Forbion Ventures VII Management B.V.C (C)Common Stock17,123,287USD 0.00USD 0SEC filing ↗
2026-08-07Anderson Michele A.Purchase (P)Common Stock1,111USD 18.00USD 19,998SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-18
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerBRVE
CIK0002131524
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history19 transaction lines from 2026-08-07 to 2026-08-07
13 P purchase lines · 0 S sale lines · 6 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.